Goldman Sachs raises AstraZeneca stock price target on HPP drug potential
PositiveFinancial Markets

Goldman Sachs has increased its stock price target for AstraZeneca, citing the potential of its HPP drug. This move reflects confidence in the company's future growth and innovation in the pharmaceutical sector.
Editor’s Note: This is significant as it indicates investor optimism about AstraZeneca's pipeline and the potential impact of its new drug on the market. A higher stock price target can attract more investors and boost the company's market presence.
— Curated by the World Pulse Now AI Editorial System